

Buprenorphine RADARS® System Analysis

Jody L. Green, PhD, CCRP

*Director of Research Administration,
Rocky Mountain Poison and Drug Center*

*Assistant Professor, School of Nursing (Research),
Vanderbilt University Medical Center*

21 March 2013



Disclosures

- Travel expenses covered by Titan Pharmaceuticals.
- RADARS® System is independently owned and operated by Denver Health & Hospital Authority, a political subdivision of the state of Colorado.
- Funding for the RADARS System comes from data subscriptions, including many manufacturers of opioids.
- Subscribers do not have any RADARS System program decision-making authority.


RADARS® System

- RADARS System monitors prescription drug abuse and diversion nationally from multiple perspectives:
 - 53 Participating Regional Poison Centers
 - 73 Opioid Treatment Programs (public & private) from 33 states
 - 280 Drug Diversion Units (nationally)
 - 6000 College Students annually (nationally)
 - Street price from crowdsourcing website (www.StreetRx.com)

Key Points

- Buprenorphine is an important drug for treatment of addiction.
- While there is an overall decreasing/stable trend of abuse/diversion for buprenorphine products as a whole, this is not true of all buprenorphine formulations.
- Accidental unsupervised buprenorphine ingestions in children are extremely dangerous and poison center data suggest that medical outcome is related to formulation.

Use of Buprenorphine has Increased




SI=single ingredient

Buprenorphine Rates


Poison Center, Drug Diversion Programs

URDD Rate (2006 – 2012)

Poison Center Intentional Exposures




Drug Diversion



SI=single ingredient

Poison Center Program

Unintentional General, Medical Outcome Children 0-12 Years (2012Q1 – 2012Q4)



SI=single ingredient

Summary

- Therapeutic use of buprenorphine is on the rise and is valued as an effective tool for treatment of addiction.
- Barriers to abuse/diversion are needed for all opioid products knowing that rates of abuse/diversion can vary significantly by formulation, even when they contain the same active ingredients.
- Toxicity of pediatric exposure is of concern with all opioids and measures to protect these children are imperative in new drug development.

Thank You

www.RADARS.org